SCHEMBL1874458

SCHEMBL1874458

O=Cc1cnc2ccc(-c3ccc(F)nc3)cn12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.40
DYRK1B Q9Y463 2/20 0.40
JAK2 O60674 1/20 0.40
RET P07949 1/20 0.40
KDR P35968 1/20 0.40
GSK3A P49840 1/20 0.40
RPS6KA3 P51812 1/20 0.40
LIMK1 P53667 1/20 0.40
MAP2K1 Q02750 1/20 0.40
MAPK14 Q16539 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
ALK Q9UM73 1/20 0.40
CYP2A6 P11509 3/20 0.37
CYP2B6 P20813 3/20 0.37
CYP2E1 P05181 1/20 0.37
DYRK2 Q92630 1/20 0.36
SCN5A Q14524 1/20 0.35
MAPT P10636 1/20 0.35
MCHR1 Q99705 3/20 0.34
FLT3 P36888 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12098007 0.80 METAP2 (0.38) FLT3PIK3CAMTORMETTGFBR1
SCHEMBL12097467 0.79 PIK3CA (0.40) FLT3PIK3CAMTORCYP11B2
SCHEMBL1866960 0.79 ERN1 (0.48) KDRCYP2A6PIK3CAMTORTGFBR1
SCHEMBL1879550 0.79 DYRK1A (0.49) DYRK1AKDRSCN5AMAPTPIK3CA
SCHEMBL12097907 0.79 PIK3CG (0.40) SCN5APIK3CAMTORCLK1TGFBR1
SCHEMBL1866743 0.78 PIK3CA (0.44) DYRK1ADYRK1BCYP2A6CYP2B6CYP2E1
SCHEMBL3787763 0.78 ADORA2A (0.40) JAK2FLT3CYP11B2
SCHEMBL12098155 0.77 PIK3CA (0.39) SCN5APIK3CAMTORCLK1MET
SCHEMBL20593153 0.77 TGFBR1 (0.43) TGFBR1
SCHEMBL12779740 0.75 FLT3 (0.46) FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741932-B2 Imidazopyridine derivatives Piramal Enterprises Limited (IN) 2014-06-03 US disclosed
US-20120232072-A1 IMIDAZOPYRIDINE DERIVATIVES PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-09-13 US disclosed
EP-2496577-A1 IMIDAZOPYRIDINE DERIVATIVES Piramal Life Sciences Limited (IN) 2012-09-12 EP disclosed
WO-2011055320-A1 IMIDAZOPYRIDINE DERIVATIVES PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232072-A1 IMIDAZOPYRIDINE DERIVATIVES IL6, IL6ST, STAT3 DYRK1A 1870/4885DYRK1B 1869/4885JAK2 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.